Most Recent Articles by Da Hee Han, PharmD
The CDC has published ACIP recommendations regarding the use of Heplisav-B.
The Bruker Maldi system is already cleared for use in identifying 333 species or species groups, including 424 bacteria and yeast species.
MF59 adjuvanted, quadrivalent influenza vaccine (aQIV) was found to be more efficacious in preventing influenza than a non-adjuvanted conventional influenza vaccine in children aged 6 through 23 months.
Study evaluated the immunogenicity and safety of 1 and 2 doses of the quadrivalent meningococcal serogroups A, C, W, Y tetanus toxoid-conjugate vaccine in individuals with functional or anatomic asplenia.
Omadacycline met all required FDA and European Medicines Agency primary endpoints in each study and demonstrated a generally safe and well-tolerated profile.
More Articles by Da Hee Han, PharmD
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- ACOG: Updated Recommendations for Influenza Vaccination During Pregnancy
- Pregnancy May Be Independently Associated With Prolonged Detection of Zika Virus RNA
- Curbing Overuse of Blood Cultures in the Emergency Department
- Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection
- Fluoroquinolone Use May Increase Risk for Aortic Aneurysm and Dissection
- Fingerstick Point-of-Care Test Allows for Single-Visit HCV Diagnoses
- Clostridium difficile Infection in the Intensive Care Setting
- Combating Medically Important Antibiotic Use in Food-Producing Animals
- Religious Exemptions vs Mandatory Vaccinations: An Expert Perspective
- 2018 Vaccination Schedule: Adults
- Possible Inhibitory Effect of HCV-Induced Steatogenesis by HBV
- Delayed Management of Severe Sepsis, Septic Shock Increases Mortality
- MenB Vaccine Gets Breakthrough Therapy Designation for Children Ages 1-9 Years
- CDC: Recommendations on the Use of Heplisav-B Published
- Non-Targeted HIV Testing in ED Acceptable to Patients